Posts

Sanofi halts eczema development of Kymab-originated OX40L antibody amlitelimab due to lack of meaningful clinical advantage and safety concerns

on

Agios second shot at sickle cell disease falls short

on

Agios scraps sickle cell program over lackluster Phase 2 data

on

Novartis drops phase 2 radioligand therapy, but CEO’s commitment to the modality unchanged

on

Roche Ends Work on Tominersen and Early-Stage Huntington's Asset After Decade of Trials

on

Sensorion advances hearing loss gene therapy programs

on

Evolving Lymphoma Market Sidelines Two J&J CAR-T Programmes

on

Johnson & Johnson Halts Phase 2 Alzheimer’s Trial After Tau Antibody Failure

on

MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results

on